Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2023 Earnings Conference Call May 3, 2023 11:30 AM ET

Company Participants

Wade Walke - SVP, IR

Brett Monia - CEO

Richard Geary - Chief Development Officer

Beth Hougen - CFO

Eugene Schneider - Chief Clinical Development Officer

Onaiza Cadoret - Chief Global Product Strategy & Operations Officer

Eric Swayze - EVP, Research

Conference Call Participants

Joseph Stringer - Needham and Company

Jessica Fye - JPMorgan

Yanan Zhu - Wells Fargo

Mike Ulz - Morgan Stanley

Yale Jen - Laidlaw and Company

Brendan Smith - TD Cowen

Tommie Reerink - Goldman Sachs

James Condulis - Stifel

Kostas Biliouris - BMO Capital Markets

Gena Wang - Barclays

Luca Issi - RBC

Myles Minter - William Blair

Operator

Good morning, and welcome to Ionis First Quarter 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded.

At this time, I would like to turn the call over to Wade Walke, Senior Vice President of Investor Relations, to lead off the call. Please begin, sir.

Wade Walke

Thank you. Before we begin, I encourage everyone to go to the Investors section of the Ionis website to view the press release and related financial tables we will be discussing today, including a reconciliation of GAAP to non-GAAP financials. We believe non-GAAP financial results better represent the economics of our business and how we manage our business. We've also posted slides on our website that accompany today's call.

With me this morning are Brett Monia, Chief Executive Officer; Richard Geary, Chief Development Officer; and Beth Hougen, Chief Financial Officer; Eric Swayze, Executive Vice President of Research; Eugene Schneider, Chief Clinical Development Officer; and Onaiza Cadoret, Chief Global Product Strategy and Operations Officer, will also join us for the Q&A portion of the call.

I would like to draw your attention to Slide 3, which contains our forward-looking statement. During this call, we will be making forward-looking language statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail.

And with that, I'll turn the call over to Brett.

Brett Monia

Thanks, Wade. Good morning, everyone, and thanks for joining us today.

This year is off to a strong start with several important achievements already, especially from our neurology franchise. Last week, the FDA granted QALSODY accelerated approval for the treatment of SOD1-ALS.